{"name": "Innovent Biologics",
 "permalink": "innovent-biologics",
 "crunchbase_url": "http://www.crunchbase.com/company/innovent-biologics",
 "homepage_url": "http://www.innoventbio.com",
 "blog_url": "",
 "blog_feed_url": "",
 "twitter_username": "",
 "category_code": "biotech",
 "number_of_employees": null,
 "founded_year": null,
 "founded_month": null,
 "founded_day": null,
 "deadpooled_year": null,
 "deadpooled_month": null,
 "deadpooled_day": null,
 "deadpooled_url": null,
 "tag_list": "",
 "alias_list": "",
 "email_address": "info@innoventbio.com",
 "phone_number": "0512-69566088",
 "description": "",
 "created_at": "Wed Nov 21 11:45:48 UTC 2012",
 "updated_at": "Wed Dec 12 07:51:12 UTC 2012",
 "overview": "\u003Cp\u003EInnovent Biologics, Inc. is a privately held biopharmaceutical company that is dedicated to the development and manufacturing of monoclonal antibodies to be marketed in China and elsewhere around the world.\u003C/p\u003E\n\n\u003Cp\u003EInnovent is funded by the venture arm of Fidelity, which is a major investment firm in the US, Lilly Ventures, and Suzhou bioBay.  The registered capital is 30Million US Dollars. The founders and senior management team of Innovent have over 70 years of combined work experience in the discovery, development and manufacture of biologics in the US, Europe and worldwide and were involved in the launch of such products as Bexxar, Conbercept, Natrecor, Oncorine, Recombivax HB, and others.\u003C/p\u003E",
 "image":
  {"available_sizes":
    [[[150,
       41],
      "assets/images/resized/0022/1443/221443v1-max-150x150.jpg"],
     [[250,
       69],
      "assets/images/resized/0022/1443/221443v1-max-250x250.jpg"],
     [[302,
       84],
      "assets/images/resized/0022/1443/221443v1-max-450x450.jpg"]],
   "attribution": null},
 "products":
  [],
 "relationships":
  [],
 "competitions":
  [],
 "providerships":
  [],
 "total_money_raised": "$25M",
 "funding_rounds":
  [{"round_code": "b",
    "source_url": "http://www.fiercepharmamanufacturing.com/press-releases/innovent-biologics-adds-25-million-expand-its-antibody-pipeline-and-its-man",
    "source_description": "Innovent Biologics Adds $25 Million to Expand its Antibody Pipeline and its Manufacturing Capabilities",
    "raised_amount": 25000000.0,
    "raised_currency_code": "USD",
    "funded_year": 2012,
    "funded_month": 11,
    "funded_day": 16,
    "investments":
     [{"company": null,
       "financial_org":
        {"name": "Lilly Asian Ventures",
         "permalink": "lilly-asian-ventures",
         "image":
          {"available_sizes":
            [[[150,
               79],
              "assets/images/resized/0005/0452/50452v1-max-150x150.png"],
             [[184,
               98],
              "assets/images/resized/0005/0452/50452v1-max-250x250.png"],
             [[184,
               98],
              "assets/images/resized/0005/0452/50452v1-max-450x450.png"]],
           "attribution": null}},
       "person": null},
      {"company": null,
       "financial_org":
        {"name": "Fidelity Biosciences",
         "permalink": "fidelity-biosciences-2",
         "image":
          {"available_sizes":
            [[[150,
               50],
              "assets/images/resized/0005/0044/50044v1-max-150x150.png"],
             [[233,
               79],
              "assets/images/resized/0005/0044/50044v1-max-250x250.png"],
             [[233,
               79],
              "assets/images/resized/0005/0044/50044v1-max-450x450.png"]],
           "attribution": null}},
       "person": null},
      {"company": null,
       "financial_org":
        {"name": "Fidelity Growth Partners Asia",
         "permalink": "fidelity-growth-partners-asia",
         "image":
          {"available_sizes":
            [[[150,
               51],
              "assets/images/resized/0026/1352/261352v1-max-150x150.jpg"],
             [[190,
               65],
              "assets/images/resized/0026/1352/261352v1-max-250x250.jpg"],
             [[190,
               65],
              "assets/images/resized/0026/1352/261352v1-max-450x450.jpg"]],
           "attribution": null}},
       "person": null}]}],
 "investments":
  [],
 "acquisition": null,
 "acquisitions":
  [],
 "offices":
  [{"description": "",
    "address1": "Building C14, 218 Xinghu St.",
    "address2": "Suzhou Industrial Park",
    "zip_code": "215123",
    "city": "",
    "state_code": null,
    "country_code": "CHN",
    "latitude": 31.2598444,
    "longitude": 120.727807}],
 "milestones":
  [],
 "ipo": null,
 "video_embeds":
  [],
 "screenshots":
  [{"available_sizes":
     [[[150,
        125],
       "assets/images/resized/0022/1444/221444v1-max-150x150.jpg"],
      [[250,
        209],
       "assets/images/resized/0022/1444/221444v1-max-250x250.jpg"],
      [[450,
        377],
       "assets/images/resized/0022/1444/221444v1-max-450x450.jpg"]],
    "attribution": null}],
 "external_links":
  []}